[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"upper-respiratory-tract-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:upper-respiratory-tract-infection":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,80],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100640315","observational-study-of-siropsedal-in-acute-cough-100640315",false,"NCT07625683","Observational Study of SIROPSEDAL in Acute Cough","Prospective Multicenter Before-After Study in Children and Adults Treated for Acute Cough With SIROPSEDAL","SIROPSEDAL","Inclusion Criteria:\n\n* Age greater than or equal to 1 year.\n* Acute cough evolving for less than 10 days.\n* Cough intensity VAS greater than 40\u002F100.\n* SIROPSEDAL prescribed independently from study participation.\n* No hospitalization required.\n* Written informed consent from the patient or from parent(s)\u002Flegal representative for minors, as applicable.\n* Able to attend the Day 7 +\u002F- 1 day visit or teleconsultation.\n* Affiliated with or beneficiary of a health insurance system.\n\nExclusion Criteria:\n\n* ACE inhibitor or sartan use.\n* Asthma or COPD.\n* Corticosteroids ongoing or within the previous 3 days.\n* Antibiotics ongoing or within the previous 3 days.\n* Antitussives ongoing or within the previous 3 days.\n* Antihistamines ongoing or within the previous 3 days.\n* Aerosol therapy ongoing or within the previous 3 days.\n* Severe signs suggesting a causal disease requiring additional investigations according to the investigator.\n* Severe signs requiring corticosteroids, aerosol therapy or centrally acting antitussive treatment according to the investigator.\n* Any contraindication listed in the instructions for use.\n* Patient under legal protection.\n* Pregnancy.\n* Intolerance, hypersensitivity or allergy to one or more product components.","ALL","1 Year",{"count":20,"type":21},124,"ESTIMATED","OBSERVATIONAL","This prospective, multicenter, observational post-market clinical follow-up study evaluates the performance and safety of SIROPSEDAL in children and adults with acute cough treated in routine clinical practice. Patients prescribed SIROPSEDAL independently of study participation will be followed for 7 +\u002F- 1 days using patient-reported outcomes including a cough visual analog scale and the Cough Symptom Score.",[25,26,27],"Acute Cough","Upper Respiratory Tract Infection","Common Cold",[29,30,31,32,33],"acute cough","cough","cough syrup","PMCF","Cough Symptom Score","NOT_YET_RECRUITING","2026-06-02",{"date":37,"type":38},"2026-06-04","ACTUAL",{"date":40,"type":21},"2026-10-15",{"date":42,"type":21},"2027-09-30",{"name":44,"class":45},"Laboratoires Elerte","INDUSTRY",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":59,"studyType":22,"phases":4,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":4},"100619618","rsv-positive-children-5-years-presenting-to-pediatric-emergency-departments-in-trkiye-trust-rsv-100619618","NCT07346963","RSV-Positive Children \u003C5 Years Presenting to Pediatric Emergency Departments in Türkiye: TRUST-RSV","Evaluation of Demographic, Clinical, and Healthcare Utilization Characteristics of Respiratory Syncytial Virus (RSV) Positive Cases Under 5 Years Presenting to Pediatric Emergency Departments in Türkiye: A Multicenter, Prospective Observational Study (TRUST-RSV)","TRUST-RSV","Inclusion Criteria:\n\n* Age \\\u003C5 years at presentation\n* Presentation during RSV season (2025-2026 )\n* RSV infection confirmed from a nasopharyngeal sample by rapid antigen test or PCR according to site capacity\n* Presentation to a participating pediatric ED with at least one of the following clinical diagnoses: upper respiratory tract infection, bronchiolitis, pneumonia, apnea, seizure\u002Fconvulsion, or myocarditis\n* Written informed consent obtained from a parent or legal guardian.\n\nExclusion Criteria:\n\n* Parent or legal guardian declines consent","28 Days","5 Years",{"count":58,"type":21},4000,"30 Days","Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infection in infants and young children and contributes substantially to pediatric emergency department (ED) visits and hospitalizations. In Türkiye, nationally representative prospective data describing the epidemiology, clinical spectrum, and resource utilization of RSV-positive children presenting to pediatric EDs remain limited. This multicenter prospective observational study aims to characterize demographic and clinical features of RSV-positive children under 5 years of age presenting to participating pediatric EDs across two consecutive RSV seasons, and to quantify key healthcare utilization outcomes, including ED observation duration, hospitalization, and intensive care unit (ICU) admission.",[62,63,64,26],"Respiratory Syncytial Virus Infection","Acute Bronchiolitis Due to Respiratory Syncytial Virus","Pneumonia",[66,67,68,69],"pediatric emergency department","multicenter","prospective","healthcare utilization","2026-01-08",{"date":72,"type":38},"2026-01-16",{"date":74,"type":21},"2026-01-01",{"date":76,"type":21},"2027-06-01",{"name":78,"class":79},"Eskisehir Osmangazi University","OTHER",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":87,"sex":17,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":92,"phases":93,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":46},"100604859","clinical-trial-to-evaluate-the-efficacy-of-lacticaseibacillus-rhamnosus-crl1505-in-the-prevention-of-upper-respiratory-tract-infections-in-children-100604859","NCT07154992","Clinical Trial to Evaluate the Efficacy of Lacticaseibacillus Rhamnosus CRL1505 in the Prevention of Upper Respiratory Tract Infections in Children","Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Lacticaseibacillus Rhamnosus CRL1505 in the Prevention of Upper Respiratory Tract Infections in a Healthy Paediatric Population","Inclusion Criteria:\n\n* Healthy children aged 3 to 12 years.\n* Signed Informed Consent by the parents\n\nExclusion Criteria:\n\n* Chronic pathological conditions, such as chronic respiratory diseases (asthma, chronic bronchitis, etc.), chronic heart diseases, chronic neurological diseases (psychomotor impairment, etc.), chronic liver diseases, chronic kidney diseases, chronic gastrointestinal diseases, hematological disorders, etc., or any other disease or condition that the investigator considers to significantly affect the health of the participating child.\n* Metabolic disorders, such as diabetes mellitus, obesity, etc.\n* Immunodeficiency, including HIV infection, chronic corticosteroid treatment, etc.\n* Nasal polyps, nasal ulcers, or other conditions that may cause nasal obstruction.\n* Regular use of medications or dietary supplements that may influence the study outcomes (immunosuppressants\u002Fimmunostimulants, including echinacea supplements, analgesics, anti-inflammatory drugs, antitussives\u002Fexpectorants, flu preparations, decongestants, antibiotics, antihistamines, probiotics, etc.) within the 4 weeks prior to the start of the clinical trial.",true,"3 Years","12 Years",{"count":91,"type":21},268,"INTERVENTIONAL",[94],"NA","Randomized, double-blind, placebo-controlled, parallel-group, clinical trial to assess the efficacy of the intake of a probiotic product composed of Lacticaseibacillus rhamnosus CRL1505 strain in reducing or preventing upper respiratory tract infections (URTIs) in a healthy paediatric population.",[26,97],"Prevention",[99,100,101,102,103,104],"prevention","upper respiratory tract infections","probiotics","microbiota","microbiome","children","RECRUITING","2025-09-08",{"date":108,"type":38},"2025-09-12",{"date":110,"type":38},"2024-12-17",{"date":112,"type":21},"2027-04",{"name":114,"class":45},"Bioithas SL"]